News

Cassava Sciences has launched the first of two Phase 3 clinical trials evaluating the safety and efficacy of simufilam, its investigational oral treatment for Alzheimer’s disease. The second trial is expected to start by year’s end, the company said in a press release. The first Phase 3 trial, called…

The first patient has been dosed in a Phase 1 study that will test multiple ascending doses of ACD856, AlzeCure Pharma‘s lead therapeutic candidate for Alzheimer’s disease. According to a company press release, the trial — the third Phase 1 study testing the oral ACD856 experimental therapy…

Hyperbaric oxygen therapy (HBOT) — treatment in which patients are given pure oxygen — prevented the biological processes responsible for the development of Alzheimer’s disease in a mouse model, a study found. Moreover, in a group of older people with memory loss, such oxygen therapy enhanced blood flow in…

Eisai has started work on a rolling submission to the U.S. Food and Drug Administration (FDA) for a Biologics License Application (BLA) for lecanemab (BAN2401), its antibody treatment for early Alzheimer’s disease. As a rolling submission, Eisai will submit each portion of its application as it is completed,…

Treatment with the investigational anti-tau monoclonal antibody semorinemab significantly slowed decline in a measure of cognition among people with mild-to-moderate Alzheimer’s disease in the Phase 2 LAURIET clinical trial, top-line results show. “The top line results of the Lauriet Phase 2 clinical trial of semorinemab are remarkable in that…

Athira Pharma, Inc will initiate an open-label extension study for two ongoing clinical trials investigating ATH-1017 to treat Alzheimer’s disease. Both clinical trials — the Phase 2/3 LIFT-AD (NCT04488419) and Phase 2 ACT-AD (NCT04491006) — are investigating ATH-1017, a small molecule designed to enhance the effect of hepatocyte growth…

People affected by Alzheimer’s disease and related dementias are invited to register for the Mayo Clinic Conference on Brain Health and Dementia, which also pays tribute to all that the community has been going through during the COVID-19 pandemic. Held virtually on Oct. 29 from 9:15am to 2:15pm…

Researcher Amir Hirsa has found a way 240 miles above the Earth’s surface to study the aggregation of proteins that are the hallmarks of Alzheimer’s and Parkinson’s diseases, and type 2 diabetes. Hirsa, PhD, is a professor of mechanical and aerospace engineering with a joint appointment in chemical and biological engineering…

A new documentary released in advance of World Alzheimer’s Day today tells the story of a Worcester, Massachusetts, photographer and art professor who captured the gradual cognitive decline of his late father through a large format black-and-white camera. “With Dad,” which is available to stream on the…

Amyloid-beta produced in peripheral organs, specifically the liver, may be implicated in the brain neurodegeneration observed in Alzheimer’s disease, according to a mouse study. The study, “Synthesis of human amyloid restricted to liver results in an Alzheimer disease–like neurodegenerative phenotype,” was published in PLOS Biology. Deposits of amyloid-beta…